Required fields are marked with *

Verification code

Merimepodib

{PARAM:[Name]}({[CAS]})
Category Hepatitis B Virus (HBV)
CAS 198821-22-6
Description Merimepodib is orally bioavailable IMPDH inhibitor.
Quotation Now

Product Information

Synonyms Merimepodib; VX497; VX-497; VX 497; MMP; VI21497; VI-21497; VI 21497.
IUPAC Name [(3S)-oxolan-3-yl] N-[[3-[[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]carbamoylamino]phenyl]methyl]carbamate
Molecular Weight 452.467
Molecular Formula C23H24N4O6
Canonical SMILES COC1=C(C=CC(=C1)NC(=O)NC2=CC=CC(=C2)CNC(=O)OC3CCOC3)C4=CN=CO4
InChI InChI=1S/C23H24N4O6/c1-30-20-10-17(5-6-19(20)21-12-24-14-32-21)27-22(28)26-16-4-2-3-15(9-16)11-25-23(29)33-18-7-8-31-13-18/h2-6,9-10,12,14,18H,7-8,11,13H2,1H3,(H,25,29)(H2,26,27,28)/t18-/m0/s1
InChIKey JBPUGFODGPKTDW-SFHVURJKSA-N
Boiling Point 571.4±50.0 °C at 760 mmHg
Flash Point 299.4±30.1 °C
Purity >98%
Density 1.4±0.1 g/cm3
Solubility In vitro:
10 mM in DMSO
Appearance white solid powder
Storage Powder:
-20°C: 3 years
4°C: 2 years
In solvent:
-80°C: 6 months
-20°C: 1 month
Complexity 652
Exact Mass 452.16958450
Index Of Refraction 1.632
In Vitro VX-497 has antiproliferative effect on lymphoid and keratinocyte cells. The antiproliferative effect of VX-497 in cells is reversed within 48 h of its removal. VX-497 has intermediate antiviral activity against a second group of viruses, which includes HSV-1, parainfluenza-3 virus, BVDV, VEEV, and dengue virus, with IC50s ranging from 6 to 19 μM. VX-497 is 100-fold more potent, with an IC50 of 380 nM and a corresponding CC50 of 5.2 μM, for a therapeutic index of 14. The antiviral activity of VX-497 in HepG2.2.2.15 cells is reversed threefold by the addition of guanosine.
In Vivo Oral administration of VX-497 inhibits the primary IgM antibody response in a dose-dependent manner, with an ED50 value of appr 30-35 mg/kg in mice. Single daily dosing of VX-497 is observed to be as effective as twice-daily dosing in this model of immune activation. GVHD developed in the vehicle-treated allografted F1 mice and treatment with VX-497 improved all manifestations of the disease significantly. The 2.9-fold increase in spleen weight in allografted animals is reduced to a 1.6-fold increase in the VX-497-treated mice. Serum IFN-gamma levels are increased 54-fold in the vehicle group while there is a 7.4-fold increase in VX-497-treated animals.
PSA 130.93000
Target HBV; HCV
Vapor Pressure 0.0±1.6 mmHg at 25°C
XLogP3-AA 2.1

TAKE YOUR NEXT STEPS

Get Started With Our Industry Experience And Client-Centric Focus!

Talk to Us

Copyright © 2025 BOC Sciences. All rights reserved.